We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Design Therapeutics Inc (DSGN) USD0.0001

Sell:$3.54 Buy:$3.55 Change: $0.21 (5.37%)
NASDAQ:0.03%
Market closed |  Prices as at close on 18 June 2024 | Switch to live prices |
Sell:$3.54
Buy:$3.55
Change: $0.21 (5.37%)
Market closed |  Prices as at close on 18 June 2024 | Switch to live prices |
Sell:$3.54
Buy:$3.55
Change: $0.21 (5.37%)
Market closed |  Prices as at close on 18 June 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The Company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its HD program is focused on the development of a potentially disease-modifying treatment for HD.

Contact details

Address:
6005 Hidden Valley Road, Suite 110
CARLSBAD
92011
United States
Telephone:
+1 (858) 2934900
Website:
https://www.designtx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
DSGN
ISIN:
US25056L1035
Market cap:
$199.99 million
Shares in issue:
56.50 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Pratik Shah
    Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
  • Sean Jeffries
    Chief Operating Officer
  • Jae Kim
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.